Trial data suggest new typhoid shot could halve infection rate

LONDON (Reuters) - A new typhoid vaccine developed by privately-held Bharat Biotech proved safe and highly immunogenic in a study and could be used to prevent millions of infections if it succeeds in final-stage clinical trials, researchers said on Friday.